[go: up one dir, main page]

AU2002224113A1 - Paramyxovirus vector encoding angiogenesis gene and utilization thereof - Google Patents

Paramyxovirus vector encoding angiogenesis gene and utilization thereof

Info

Publication number
AU2002224113A1
AU2002224113A1 AU2002224113A AU2411302A AU2002224113A1 AU 2002224113 A1 AU2002224113 A1 AU 2002224113A1 AU 2002224113 A AU2002224113 A AU 2002224113A AU 2411302 A AU2411302 A AU 2411302A AU 2002224113 A1 AU2002224113 A1 AU 2002224113A1
Authority
AU
Australia
Prior art keywords
utilization
vector encoding
angiogenic genes
paramyxovirus vector
angiogenesis gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224113A
Inventor
Masayuki Fukumura
Mamoru Hasegawa
Xiaogang Hou
Katsuo Sueishi
Yoshikazu Yonemitsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnavec Research Inc
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Publication of AU2002224113A1 publication Critical patent/AU2002224113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.
AU2002224113A 2000-11-27 2001-11-27 Paramyxovirus vector encoding angiogenesis gene and utilization thereof Abandoned AU2002224113A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-359374 2000-11-27
JP2000359374 2000-11-27
PCT/JP2001/010323 WO2002042481A1 (en) 2000-11-27 2001-11-27 Paramyxovirus vector encoding angiogenesis gene and utilization thereof

Publications (1)

Publication Number Publication Date
AU2002224113A1 true AU2002224113A1 (en) 2002-06-03

Family

ID=18831146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224113A Abandoned AU2002224113A1 (en) 2000-11-27 2001-11-27 Paramyxovirus vector encoding angiogenesis gene and utilization thereof

Country Status (12)

Country Link
US (3) US20040005296A1 (en)
EP (1) EP1344829B1 (en)
JP (1) JP4212357B2 (en)
KR (1) KR100812884B1 (en)
CN (1) CN100357443C (en)
AT (1) ATE393235T1 (en)
AU (1) AU2002224113A1 (en)
CA (1) CA2430112C (en)
DE (1) DE60133767T2 (en)
DK (1) DK1344829T3 (en)
ES (1) ES2305138T3 (en)
WO (1) WO2002042481A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143892C (en) * 1995-11-01 2004-03-31 株式会社载体研究所 Recombinant Sendai virus
EP1094115B1 (en) * 1998-07-03 2009-05-06 Dnavec Research Inc. (-)-strand rna virus vector for nerve cells
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
KR100776086B1 (en) * 1999-09-06 2007-11-15 가부시키가이샤 디나벡크 겐큐쇼 Paramyxoviruses with Modified Transcription Initiation Sequences
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
CN1248740C (en) 2000-03-30 2006-04-05 株式会社载体研究所 AIDS virus vaccine with use of sendai virus vector
CN100531802C (en) * 2000-06-01 2009-08-26 株式会社载体研究所 Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
EP1297852A4 (en) * 2000-06-27 2004-12-29 Dnavec Research Inc Virus vector for introducing gene into renal cells
JP2002142770A (en) * 2000-11-08 2002-05-21 Dnavec Research Inc Paramyxovirus vector for transporting gene to circulatory system
CA2430112C (en) * 2000-11-27 2010-07-27 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and use thereof
EP1504766A4 (en) * 2002-04-30 2006-11-02 Dnavec Research Inc Drug- or gene-carrier composition having lowered hemagglutinin activity
KR20050057136A (en) * 2002-09-04 2005-06-16 가부시키가이샤 디나벡크 겐큐쇼 Process for producing virus vector containing membrane protein having sialic acid-binding activitiy in envelope with the use of gram-positive bacterium-origin neuraminidase
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
JPWO2005001082A1 (en) * 2003-06-30 2006-08-10 株式会社ディナベック研究所 Negative-strand RNA viral vector carrying a gene with a highly mutated region
DE10333217A1 (en) * 2003-07-22 2005-03-10 Biomay Prod & Handel Polypeptides, encoding nucleic acids from the mold Cladosporium herbarum and their preparation and use in diagnostics and therapy
KR20070004637A (en) * 2004-01-22 2007-01-09 가부시키가이샤 디나벡크 겐큐쇼 Method of producing viral vector
WO2005097988A1 (en) * 2004-03-23 2005-10-20 Dnavec Research Inc. Bone marrow-relevant cell participating the maintenance and/or repair of tissue
CN101351557A (en) * 2005-10-28 2009-01-21 生物载体株式会社 Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA virus spike protein
KR101336386B1 (en) * 2011-06-17 2013-12-04 전북대학교병원 Revellent lymph blood vessel
MX376776B (en) 2013-03-15 2025-03-07 Elixirgen Therapeutics Inc Methods of using zscan4 for rejuvenating human cells
EP4414451A3 (en) * 2013-04-26 2025-04-23 Genomatica, Inc. Microorganisms and methods for production of 4 hydroxybutyrate, 1,4-butanediol and related compounds
US20160312261A1 (en) * 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
WO2021174121A1 (en) * 2020-02-27 2021-09-02 Icahn School Of Medicine At Mount Sinai Vegfr-3-activating agents and oncolytic viruses and uses thereof for the treatment of cancer
US20250340899A1 (en) 2022-04-25 2025-11-06 Tokiwa-Bio Inc. Rna virus-derived chimeric envelope protein and rna virus vector having same
EP4474521A1 (en) 2023-06-07 2024-12-11 FN Herstal S.A. Method for coating firearm barrel

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
GB8821795D0 (en) 1988-09-16 1988-10-19 Erba Carlo Spa New derivatives of human/bovine basic fibroplast growth factor
IT1237795B (en) * 1989-12-22 1993-06-17 Erba Carlo Spa FIBROBLASTIC GROWTH FACTORS FOR USE IN THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS.
FR2717495B1 (en) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
DE69634904T2 (en) * 1995-10-31 2006-05-18 Dnavec Research Inc., Tsukuba NEGATIVE STONE RNA VIRUS WITH SELF-ACTIVE REPLICATION ACTIVITY
CN1143892C (en) * 1995-11-01 2004-03-31 株式会社载体研究所 Recombinant Sendai virus
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
CA2368944C (en) 1999-05-18 2010-07-27 Dnavec Research Inc. Paramyxovirus-derived rnp
DE60035589T2 (en) 1999-05-18 2008-04-17 Dnavec Research Inc., Tsukuba VIRAL PARAMYXOVIRIDAE VECTOR WITH A DEFECTIVE CROP PROTEIN GEN
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
WO2001032898A2 (en) 1999-11-02 2001-05-10 Dnavec Research Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
SE0000285D0 (en) * 1999-12-07 2000-01-31 Mika Lahtinen Medical implant
EP1251174A4 (en) * 2000-01-19 2003-05-02 Dnavec Research Inc Use of paramyxovirus vector in gene transfer into blood vessel
CN100531802C (en) 2000-06-01 2009-08-26 株式会社载体研究所 Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
CA2424992A1 (en) * 2000-10-06 2003-04-04 Dnavec Research Inc. Paramyxovirus vectors for introducing foreign genes into skeletal muscle
JP2002142770A (en) 2000-11-08 2002-05-21 Dnavec Research Inc Paramyxovirus vector for transporting gene to circulatory system
CA2430112C (en) * 2000-11-27 2010-07-27 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and use thereof
WO2005097988A1 (en) * 2004-03-23 2005-10-20 Dnavec Research Inc. Bone marrow-relevant cell participating the maintenance and/or repair of tissue

Also Published As

Publication number Publication date
US20100158867A1 (en) 2010-06-24
ATE393235T1 (en) 2008-05-15
CA2430112C (en) 2010-07-27
CA2430112A1 (en) 2003-05-27
JP4212357B2 (en) 2009-01-21
DE60133767T2 (en) 2009-06-25
WO2002042481A1 (en) 2002-05-30
KR100812884B1 (en) 2008-03-11
EP1344829A4 (en) 2005-01-05
JPWO2002042481A1 (en) 2004-03-25
DK1344829T3 (en) 2008-09-01
ES2305138T3 (en) 2008-11-01
KR20030074627A (en) 2003-09-19
EP1344829B1 (en) 2008-04-23
CN100357443C (en) 2007-12-26
EP1344829A1 (en) 2003-09-17
US8211868B2 (en) 2012-07-03
DE60133767D1 (en) 2008-06-05
CN1487999A (en) 2004-04-07
US20110212059A1 (en) 2011-09-01
US20040005296A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
AU2002224113A1 (en) Paramyxovirus vector encoding angiogenesis gene and utilization thereof
AU2001226246A1 (en) Antisense inhibition of ptp1b expression
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2002010378A3 (en) Antisense modulation of ptp1b expression
WO2003023005A3 (en) Antisense modulation of pka regulatory subunit rii alpha expression
AU2001290706A1 (en) Antisense modulation of clusterin expression
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2003018600A3 (en) Antisense modulation of microsomal triglyceride transfer protein expression
WO2001029175A3 (en) Antisense modulation of fra-1 expression
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2002062951A3 (en) Antisense modulation of casein kinase 2-alpha prime expression
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
WO2003012031A3 (en) Antisense modulation of stearoyl-coa desaturase expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003030826A3 (en) Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2002050244A3 (en) Antisense modulation of histone deacetylase 1 expression
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2002024864A3 (en) Antisense modulation of syntaxin 4 interacting protein expression
WO2003044167A3 (en) Antisense modulation of human fxr expression
WO2003040161A3 (en) Antisense modulation of activating transcription factor 3 expression
WO2002041836A3 (en) Antisense modulation of src-1 expression